Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."

01 Oct 2017


File List, RICO

1988 Steere says Lyme is like a B cell leukemia

Assoc Blogs-n-Webs:




Fungal Exosomes Inhibit Apoptosis

IDSA: "Vaccines serve the mfgs, not their victims"


BlumenthalAntiTrust Lawsuit

Exosomes, Blebs


CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler, 1994
BarbourFish, 1993
Dearborn, 1994

Pathogenic Fungi

Bush's warcrimes, Oct 2000





CNN Anthony Fauci LYING on national television - with Lou Dobbs, saying, we have a Lyme vaccine

"We've had an effective vaccine, but it's the kind of vaccine that you have to essentially vaccinate people each year. And from the standpoint of it's use, it has not been used as efficiently as it could have been used. So scientifically, we had a vaccine and still do have a vaccine, but it's not really well used." -- Fauci

That was after the vaccine had already been removed from the market because of Tuft's publication in a patent that OspA binds the HLA molecule or is a superantigen or toxin in some people.  See the Patents video for the patent number.


DOBBS: And, of course, the concerning, the frightening aspect of this is that doctors today are not Lyme disease literate and still have not come up with effective treatments and yet we see new diseases emerging here.

DOBBS: Louise, thank you very much. Louise Schiavone from Washington.

Dr. Anthony Fauci is director of the National Institutes for Health. He says emerging diseases are noting new. They're spread not surprising given the nature of a shrinking world in which we all now live. Dr. Anthony Fauci joins us now from Washington. Good to have you with us.


DOBBS: This week, Doctor, we have been focusing on this show on emerging diseases and it is concerning. With international travel, with the number of diseases that are emerging, how would you rank the level of concern on the part of your organization and other public health agencies?

FAUCI: Well, it's a level of concern that spurs you to be very vigilant to increase your preparedness. It's not the kind of concern where you wring your hands and feel panicky that you have an impending disaster that it's just around the corner, but it is a state of mind of taking it very seriously.

Emerging and reemerging diseases have been with us from the beginning of civilization and will continue to be with us because of that special relationship between microbes and humans, and they emerge. They emerge as new diseases or they reemerge as older diseases, only under different forms.

DOBBS: The capacity, though, by which they can be transmitted, to populations centers literally all over the planet is entirely new. And amongst those diseases, Dr. Fauci, which is the most concerning to you? Which do you think deserves the highest priority on the part of U.S. public health officials?

FAUCI: Well, Lou , right now, the unknown is certainly something that you can't quantitate because we could have the emergence of a disease like SARS of which we are still having a problem with right now. Although it's plateaued that's a totally new disease. So there's a vast unknown.

But of the things that we know of that most concerning to many public health officials like myself is a pandemic influenza because we know in that 1918, influenza killed 40 or some odd more million people worldwide, and about 750,000 people in the United States in one year, in 1918. And there certainly is a possibility that we may have the emergence of, again, another pandemic, deadly flu.

So that's of considerable concern to me.

DOBBS: Debilitating, as well, but of a lesser threat in terms of its fatality rate, its mortality rate, is lyme disease. It is striking that in a period of 30 years, treatment is so -- if you will, primitive. Cures not at hand. Diagnosis is often not available. Too many doctors simply not literate. How can this be?

FAUCI: Well, that's exactly not quite the case, Lou. In lyme disease, if you get acute lyme disease, the antibiotic treatment of that is really quite effective in curing people of it. What happens that sometimes it goes undiagnosed or it goes into into a chronic form. And once it goes into a chronic form, then you have a significant problem.

We've had an effective vaccine, but it's the kind of vaccine that you have to essentially vaccinate people each year. And from the standpoint of it's use, it has not been used as efficiently as it could have been used. So scientifically, we had a vaccine and still do have a vaccine, but it's not really well used.

The problem is when you get either an undiagnosed case that goes on smoldering without appropriate treatment or you get into the chronic phase which can be quite debilitating.

DOBBS: And turning to West Nile virus, we are coming into -- May and June, record wet weeks in the east. Mosquitoes will be certainly in abundance. And West Nile, the danger from it even greater. How concerned are you about West Nile disease?

FAUCI: Certainly West Nile is of concern. Remember, it came for the first time in the United States in 1999 just a handfuls of cases. Last year, we had over 4,100 cases with 285 deaths.

When you have the seasons like we have now with the wetness and then you have a following a dry season, we'll wind up with some significant problems. I don't think there's any doubt. We have already identified in about 24 states animals that have already been this season identified to be infected with West Nile. That's a bad sign.

So we're girding ourselves with a good deal of surveillance and we may have to implement some significant mosquito control measures depending on how things shake out over the next couple of months. So it's something we need to keep a very serious eye on.

DOBBS: Dr. Anthony Fauci of the National Institutes of Health, we thank you very much for being with us.

PATENT DATABASE  (Fauci, Inventor Name)

6,548,055     6,190,656   

Thanks, Fauc'.  This may be the antidote to Neuroborreliosis (The Mark Klempner Seronegative kind), and post LymeRIX syndrome (Immune suppression). 



The present invention pertains to a method for activating the immune system of a patient by intermittently administering interleukin-2 (IL-2) to that patient. Such administration of IL-2 can optionally be combined with other therapies, such as anti-retroviral, anti-bacterial or anti-fungal therapies, suitable for treatment of the patient's condition. This invention also relates to an approach to gene therapy that entails administering IL-2 to a patient so as to facilitate in situ lymphocyte transduction by a retroviral vector also administered to the patient.


Attempts at immune activation and restoration in the past have utilized bone marrow transplantation or lymphocyte transfers (H. C. Lane et al., Ann. Internal Med. 113: 512-19 (1990)), immunomodulating agents such as immuthiol (J. M. Lang et al., Lancet 24: 702-06 (1988)) or isoprinosine (C. Pedersen et al., N. Engl. J. Med. 322: 1757-63 (1990)), and recombinant cytokines such as interferon alpha (IFN-.alpha.) and IL-2. H. C. Lane et al., Ann. Intern. Med. 112: 805-11 (1990); H. C. Lane et al., J. Biol. Response Mod. 3, 512-16 (1984); D. H. Schwartz et al., J. Acquir. Immune Defic. Syndr. 4, 11-23 (1991); P. Mazza et al., Eur. J. Haematol. 49: 1-6 (1992); H. W. Murray et al., Am. J. Med. 93: 234 (1992); H. Teppler et al., J. Infect. Dis. 167: 291-98 (1993); P. Volberding et al., AIDS Res. Hum. Retroviruses 3: 115-24 (1987). These studies have resulted in minimal or only transient immune system restoration.

The use of biologic response modifiers in general, and of IL-2 in particular, is an active area of clinical research. Interleukin-2 is a T cell-derived lymphokine with a number of immunomodulating effects including activation, as well as induction of proliferation and differentiation, of both T and B lymphocytes. K. A. Smith, Science 140: 1169-76 (1988). Exogenous IL-2 has been shown in vitro to increase the depressed natural killer cell activity and cytomegalovirus-specific cytotoxicity of peripheral blood mononuclear cells from patients with AIDS, as well as to increase IFN-.gamma. production by lymphocytes from patients with AIDS. A. H. Rook et al., J. Clin. Invest. 72: 398-403 (1983); H. W. Murray et al., loc. cit. 76: 1959-64 (1985).

IL-2 given by high dose infusion has been employed in the treatment of renal cell carcinoma and melanoma. J. Nat'l Cancer Inst. 85(8): 622-32 (1993). For example, doses of 36 million international units (MU) given continuously over a period of 24 hours has been used in the treatment of cancer (18 MU is equivalent to about 1 mg protein). Lancet 340: 241 (1992). The use of high doses of IL-2 generally is not well tolerated by patients, however, and side effects are more pronounced at such high levels.

"If you want to talk about ethics," said Dr. Anthony Fauci of the National Institutes of Health in Maryland, "you want to make sure something works before you announce it."

ROTFL, Yeahright, ethics. 


The conduct of Dr. Fauci, and others, has compromised the basic principles of ethics, public trust and the most fundamental concepts that define "scientific integrity".

"The conduct of Dr. Fauci, and others, has compromised the basic principles of ethics, public trust and the most fundamental concepts that define 'scientific integrity'.  "


Greater potential to transmit HIV congenitally if you are black:

Does this account for the ineptitude in the development of an HIV vaccine?